Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim
Part 2 of the ASH 2015 interview Professor Waseem Qasim kindly gave BSB at the American Society of Hematology (ASH) discusses the poster he presented at the meeting (Abstract 2046:) “First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL.”
Prof Qasim is a Consultant in Paediatric Immunology and Bone Marrow Transplantation at Great Ormond Street Hospital (GOSH) and Professor of Cell & Gene Therapy at the Institute of Child Health which is part of University College London (UCL).
The “devil is in the detail” so it was a privilege to be taken through the case by Prof Qasim, and in the process, better understand the treatment rational, as well some of the challenges and unanswered questions that will need to be addressed moving forwards.
The first-in-man use of the UCART19 allogeneic CAR T cell therapy from Cellectis was done under the Compassionate Use guidelines of the UK Medicines and Health Products Regulatory Agency (MHRA). A phase 1 clinical trial is planned for early 2016.
Subscribers can login to read more or you can purchase access.
This content is restricted to subscribers
